Abstract
Despite troublesome safety problems with past entrants into this market, the veritable epidemic of overweight and obesity continues to make this sector an extremely attractive target for pharmaceutical developers. This new title provides a considered view of the market for medical interventions in the battle against obesity, including U.S. and worldwide market size and growth forecasts, competitive market share and extensive pharmaceutical pipeline information.
The report discusses both prescription and OTC drug markets and surgical interventions. Market size and growth rates are provided through 2010 for:
- Prescription Appetite Suppressants
- Prescription Lipase Inhibitors
- OTC Appetite Suppressants
- OTC Fat Substitutes
- Surgical Intervetion (dollar- and procedure volumes)
Complete epidemilogical data, detailed descriptions of over 50 compounds in development for this sector, and profiles of 14 top suppliers are provided as well.
Table of Contents
Chapter One: Executive Summary
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction
- Overview of Obesity and Weight Management
- Definition of Overweight and Obesity
- Homeostatic Mechanisms Controlling Energy Balance
- Linking Energy Stores in Body Fat with the Hypothalamus
- Insulin as the Sensor of Energy Stores in Fat
- Integration and Effect on Energy Balance
- Regulation of Energy Expenditure and Food Intake
- Energy Expenditure
- Food Intake
- Pathophysiology of Obesity
- Obesity Disorder of the Homeostatic Control of Energy Balance
- Genetic Factors
- Food Intake
- Physical Exercise
- Causes of Overweight and Obesity
- Genetics
- Environmental
- Socioeconomic
- Health Risks
- Economic Consequences
- Demographics
- Obesity Management
Chapter Three: Issues and Trends
- Over-the Counter Xenical
- Cortisol and Obesity
- Weight and Height Trends
- Educational Efforts of Physical Activity
- Sedentary Behavior in Overweight and Obese Persons
- Role of Physical Activity in Body Weight Regulation
- Educating Patients About the Benefits of Activity
- Cardiovascular and All-Cause Mortality
- Cardiovascular Risk Factors
- Fat and Muscle During Weight Loss
- Physical and Psychologic Well-being
- Long-term Weight Maintenance
- Fat Gene Mapping Tool
- Laser Melts Fat
- Ciliary Neurotrophic Factor Update
- Drinking and Obesity
- Exercise Gene
- Trends in Childhood Obesity
- Effect of Modernization on Obesity
- Insurance Coverage Issues
- Medicare
- Medicaid
- Medicare Coverage of Bariatric Surgery
- Selected Weight Loss Programs
Chapter Four: Prescription Pharmaceutical Market
- Description of Products
- Appetite Suppressants
- Sympathomimetic Amine
- Monoamine Reuptake Inhibitor
- Lipase Inhibitors
- Market Size and Growth
- World Market
- World Market and U.S. Market Analysis
- Competitive Analysis
Chapter Five: Over-the-Counter Drugs
- Overview
- Description of Products
- Appetite Suppressants
- Noradrenergic Agents
- Caffeine-based Agents
- Benzocaine-Based Agents
- Fat Substitutes
- Others
- 5HTP-Trptophan
- Hoodia
- Market Size and Growth
- World Market
- World Market and U.S. Market Analysis
- Competitive Analysis
Chapter Six: Surgical Interventions
- Overview
- Description of Products
- Restrictive Surgery
- Combined Restrictive and Malabsorptive Surgery
- Market Size and Growth
- World Market
- World Market and U.S. Market Analysis
- Procedure Volumes
Chapter Seven: Pharmaceutical Research and Development
- Overview
- Description of Products
- 5HT2-C Agonists
- APD 356
- WAY 629 & WAY 909
- 5HT-6 Antagonists (BVT.5182)
- Adiponectin (ACRP30 Famoxin)
- Amylin Analogs (Symlin AC137)
- Angiogenesis Inhibitors (TNP-470)
- B-3AR Agonists
- Botanical P57
- Calpain-3
- Cannabinoid-1 Receptor antagonists
- Acomplia
- L-000899055
- SLV319
- SR 147778
- CCK-A Agonists
- Cholesterol Metabolites (MSI-1436)
- Cholesterol Transport Inhibitors (FM-VP4)
- Ciliary Neurotrophic Factor (CNTF) (Axokine)
- Extendin-4 (AC3174)
- Fatty Acid Synthase Inhibitor (C75)
- Fibroblast Growth Factor-1 Inhibitor
- FIT Gene and Ion Channel (CSX121, CSX 102 and CXS-829)
- Ghrelin Antagonist
- Histamine-3 Antagonists
- A-331440
- NNC 0038-0000-1202
- Human Growth Hormone Fragments (AOD 9604)
- Leptin Agonists (CBT 1452)
- Lipase Inhibitors
- ATL 962
- GT389-255
- Melanin Concentrating Hormone-1 Receptor Antagonists
- A-798
- GW803430
- NGX-1
- SNAP 7941 SNAP94847
- Melanocortin-4 Receptor Agonists
- BIM-22103
- NNC 70-619
- Microsomal Triglyceride Transfer Protein (MTP) Inhibitor (SLx-4090)
- Neuropeptide y2 Receptor Antagonist
- Neuropeptide Y Agonist (TM30338 and TM30339)
- Neuropeptide Y5 Receptor Antagonist (S-2367)
- Nicotine Receptor Ligand (TC-2216/TC-2286)
- Obestatin
- Oleoyl-estrone
- Oleoylethanolamide
- Osmotin
- Oxyntomodulin
- Peroxisome Proliferator Activated Receptor (GW501516)
- Peroxisome Proliferator Activated Receptor-Pan Agonist (DRL 11605)
- Gut Hormone Peptide (PYY)
- PPY3-36
- AC 162352
- Retinoid X Receptor: Peroxisome Proliferator Activated
- Receptor Agonists (LG100268)
- RIP140 Inhibitor
- Selective Androgen Receptor Modulator (SARM) (Ostarine)
- Stearoyl-COA Desaturase-1
- Thyroid Hormone-B Receptor Agonist (KB-2115)
- Vaccines (CYT009)
- Others
- BDC-03
- BL-2040
- HMR 1426
- Orexin
Chapter Eight: World Market Summary
- Overview
- Total market Size and Forecast
- Competitor Analysis
Chapter Nine: Corporate Profiles
- Abbott Laboratories
- Alizyme
- Arena Pharmaceuticals
- ChemGenex Pharmaceuticals
- GlaxoSmithKline plc
- Ligand Pharmaceuticals, Inc
- Manhattan Pharmaceuticals, Inc
- Merck & Company, Inc.
- Metabolic Pharmaceuticals Limited
- Novartis
- Proctor & Gamble
- Regeneron Pharmaceuticals Inc
- Roche Group
- Sanofi-Aventis
